ArtVentive Medical Group announced that it has received US Food and Drug Administration (FDA) clearance for the Endoluminal Occlusion System (EOS).
Designed for use in the peripheral vasculature, the EOS offers immediate, complete and total occlusion in arterial and venous settings.
ArtVentive CEO Jim Graham stated, "This is a testament to the hard work and dedication of our entire team. The EOS technology platform serves unmet clinical needs and provides a foundation for future innovation to expand into additional treatment areas. We look forward to sharing the technology with physicians in the U.S. and additional international markets as we commence our commercialization efforts."
The ArtVentive EOS is catheter-based, self-expandable and facilitates permanent or temporary occlusion of peripheral body lumens, cavities occurring within the body’s vascular system and organ network.
The ArtVentive EOS is designed to serve as a safe and reliable alternative to major surgery in certain cases. This technological innovation brings current interventional, image-guided techniques to a new level of sophistication, with the potential to resolve significant health issues.
The ArtVentive EOS serves as a proprietary technology platform for several major clinical areas, including peripheral and neurological vascular disorders, women’s health (minimally invasive contraceptive and birth control), interventional cardiology, pulmonary and interventional oncology procedures.